The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1394
July 9, 2012
View Complete Issue         Table of Contents 2019 
Vismodegib (Erivedge) for Basal Cell Carcinoma
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Vismodegib (Erivedge) for Basal Cell Carcinoma
July 9, 2012 (Issue: 1394)
The FDA has approved vismodegib (vis moe deg´ ib; Erivedge – Genentech), the first hedgehog (Hh) pathway inhibitor, for oral treatment of metastatic basal cell cancer, locally advanced basal cell carcinoma that has recurred after surgery, or...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Vismodegib (Erivedge) for Basal Cell Carcinoma
Article code: 1394a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.